Multi-omics integrative analysis reveals shared immunometabolic features between breast cancer and type 2 diabetes through CLEC7A associated myeloid immune reprogramming and the MIF signaling axis
This multi-omics study reveals that breast cancer and type 2 diabetes share immunometabolic mechanisms driven by CLEC7A-associated myeloid immune reprogramming and the MIF–CD74/CXCR4 signaling axis, offering new insights into their cross-disease inflammatory communication and potential therapeutic targets.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Two common conditions, breast cancer and type 2 diabetes, often appear together in the same people, creating a complex health challenge. While doctors have long observed that women with type 2 diabetes face a slightly higher risk of developing breast cancer, the biological reason for this link has remained a mystery. It is not a simple case of one disease directly causing the other through a single genetic flaw. Instead, scientists suspect the connection lies in a shared internal environment shaped by how the body handles energy and inflammation. When the body struggles to manage blood sugar and fat, it enters a state of chronic, low-level stress that affects how immune cells function. This study set out to map the invisible conversation between these two diseases, looking for a common language spoken by the body's immune system that might explain why they travel together.
Researchers approached this puzzle by treating the body's genetic data like a vast library of instructions. They gathered thousands of genetic profiles from patients with breast cancer and others with type 2 diabetes, searching for specific genes that behaved similarly in both groups. By comparing these massive datasets, they filtered out the noise to find a small set of thirty-seven genes that were altered in both conditions. These shared genes were not random; they were heavily involved in how cells handle stress and how the immune system responds to threats. To understand which of these genes were the most important, the team built a network map showing how the proteins produced by these genes interact with one another. This map highlighted fifteen key players, but only one stood out as behaving consistently in the same way across both diseases: a gene called CLEC7A.
The story of CLEC7A is one of location and timing. When the researchers looked at these genes under a microscope of single-cell resolution, they found that CLEC7A was not active in the cancer cells themselves or in the general tissue. Instead, it was a signal specifically turned on in a type of white blood cell known as a myeloid cell, which includes monocytes and macrophages. These cells act as the body's first responders and managers of inflammation. In both the tumor environment of breast cancer and the blood of people with type 2 diabetes, these myeloid cells were reprogrammed to express high levels of CLEC7A. This suggests that the link between the two diseases is not a direct genetic mutation but rather a shared state of immune readiness, where the body's defense cells are stuck in a mode of chronic alertness driven by metabolic stress.
The investigation then turned to how these reprogrammed cells talk to one another. The researchers discovered that in both diseases, these myeloid cells were actively using a specific communication channel involving a molecule called MIF and its receptors. This signaling pathway acts like a loudspeaker, amplifying inflammation and helping to reshape the environment around the tumor or within the blood vessels. The study found that the presence of CLEC7A was tightly linked to the activity of this MIF signaling system. In essence, the cells carrying the CLEC7A marker were the ones most engaged in this inflammatory conversation. This finding supports a model where the metabolic chaos of diabetes primes the immune system, and when these primed cells encounter a tumor, they help create a supportive environment for the cancer to grow, rather than fighting it.
Despite these strong connections, the researchers were careful to clarify what this gene does not do. They tested whether high levels of CLEC7A could predict how long a patient would survive, but the data showed no such link. This means that while the gene is a reliable marker of the immune system's state, it is not a crystal ball for patient outcomes. Furthermore, the study ruled out the idea that a single genetic cause drives both diseases in a straightforward line. Instead, the evidence points to a systemic issue where the body's metabolic struggles create a fertile ground for inflammation, which in turn alters how immune cells behave. The research suggests that the shared risk between diabetes and breast cancer is a consequence of this metabolic inflammation, with CLEC7A serving as a clear signpost of the immune cells caught in the middle.
The implications of this work extend beyond just understanding the link between two diseases. By identifying CLEC7A and the MIF signaling axis as central players, the study offers a new way to think about treatment. If the connection is driven by this specific immune reprogramming, then therapies that calm this inflammatory conversation or target these specific myeloid cells could potentially benefit patients with both conditions. The study does not claim to have found a cure, but it has successfully mapped a critical piece of the biological landscape. It reveals that the body's response to metabolic stress and its response to cancer are not separate events, but part of a single, interconnected system where the immune cells act as the bridge, carrying the signals of one disease into the territory of the other.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.